Łusiak-Szelachowska Marzanna, Międzybrodzki Ryszard, Rogóż Paweł, Weber-Dąbrowska Beata, Żaczek Maciej, Górski Andrzej
Bacteriophage Laboratory, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (HIIET PAS), 53-114 Wrocław, Poland.
Phage Therapy Unit, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences (HIIET PAS), 53-114 Wrocław, Poland.
Antibiotics (Basel). 2022 Oct 5;11(10):1358. doi: 10.3390/antibiotics11101358.
Phages are immunogenic and may evoke an immune response following their administration. Consequently, patients undergoing phage therapy (PT) produce phage-neutralizing serum antibodies. The clinical significance of this phenomenon for the success or failure of the therapy is currently unclear. Interestingly, even a strong anti-phage humoral response does not exclude the success of PT. On the other hand, it cannot be ruled out that phage-antibody complexes may be trapped in tissues and organs causing injury and late complications of PT. Therefore, patients should be monitored for the presence of serum antibodies and therapy discontinued if their level is high. Our preliminary data suggest that the kinetics of the disappearance of those antibodies may vary from patient to patient and in some cases may take more than a year.
噬菌体具有免疫原性,给药后可能引发免疫反应。因此,接受噬菌体疗法(PT)的患者会产生噬菌体中和血清抗体。目前尚不清楚这种现象对治疗成败的临床意义。有趣的是,即使是强烈的抗噬菌体体液反应也不排除PT治疗成功。另一方面,不能排除噬菌体 - 抗体复合物可能被困在组织和器官中,导致PT的损伤和晚期并发症。因此,应监测患者血清抗体的存在情况,如果抗体水平较高则停止治疗。我们的初步数据表明,这些抗体消失的动力学在患者之间可能有所不同,在某些情况下可能需要一年以上的时间。